Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/195065 
Year of Publication: 
2019
Series/Report no.: 
ZEW Discussion Papers No. 19-011
Publisher: 
ZEW - Leibniz-Zentrum für Europäische Wirtschaftsforschung, Mannheim
Abstract: 
This paper is concerned with exploring the implications of replicability issues over the medical innovation process. Each research setting is characterized by a specific level of replicability, variability increasing with the complexity of the testing settings. The study introduces new measures to quantify the research efforts across different medical experimental settings. Doing so allows to map the dynamics of knowledge along the medical R&D spectrum and over time. The lack of replicability of experiments was overcome by recombining technological knowledge coming from distinct uses (laboratory tool and other medical applications) with clinical insights. The citation analysis suggests that science, technology, and clinical learning interact strongly and have an uneven importance over time. The study stresses the importance of economics of scope between experimenting and technology developments. In this process, a new type of chemotherapy emerged without a centralized institution governing the testing effort. Research and innovation policy implications are discussed.
Subjects: 
medical innovation
knowledge translation
replication
instrumentation
JEL: 
I12
O31
D83
D85
Document Type: 
Working Paper

Files in This Item:
File
Size
790.59 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.